[Recombinant alpha-interferon (reaferon) in the treatment of patients with chronic myeloleukemia].
The authors relate the results of a clinical study of the Soviet recombination alpha-interferon (reaferon) in 46 patients with chronic myeloleukemia at different stages of the disease. Reaferon is shown to be tolerated well, to have a low percentage of side effects in particular high temperature and allergic reactions, to possess no hepato-, nephro- and cardiotoxicity. It has been proved that in patients with chronic myeloleukemia reaferon produces an independent antiproliferative effect and is capable of controlling the leukemic process without chemotherapeutic drug (in the stable chronic phase of the disease). Doses and administration of reaferon for a long time are suggested in order to prolong the disease course.
Khoroshko
N D
ND
Savchenko
V G
VG
Kholopova
E I
EI
Kotel'nikov
V M
VM
Zakharova
A V
AV
Semenova
E A
EA
Marchenko
V I
VI
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001752:Blast Crisis / Q000628:therapy; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D010677:Philadelphia Chromosome; D011994:Recombinant Proteins; D013997:Time Factors
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
Rekombinantnyĭ al'fa-interferon (reaferon) v lechenii bol'nykh khronicheskim mieloleĭkozom.